Dataset Information

Transcriptomic profiling of LNCaP cells treated with enzalutamide, olaparib, or combination across multiple time points

ABSTRACT: To explore the mechanisms underpinning the combinatorial effects of androgen pathway and PARP inhibition on global gene expression in prostate cancer, we performed RNA sequencing analysis in LNCaP prostate cancer cells. Cells were treated with either single agents or the combination, and transcriptomic changes were asssed at early (8 hours), intermediate (24 hours), and late (72 hours) timepoints to assess temporal dynamics of treatment response. Comparative analyses between single-agent and combination treatments enabled the characterisation of transcriptional programs induced by the combinatorial regimen.

ORGANISM(S): Homo sapiens

PROVIDER: GSE303975 | GEO | 2025/08/04

REPOSITORIES: GEO

ACCESS DATA

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Project description:Androgen receptor (AR)-targeting prostate cancer drugs, which are predominantly competitive ligand binding domain (LBD)-binding antagonists, are inactivated by common resistance -mechanisms. It is important to develop next-generation mechanistically-distinct drugs to treat castration- and drug- resistant prostate cancers. Here, we describe a second-generation AR pan-antagonist (UT-34) that degrades the AR and AR splice variants. UT-34 inhibits the wild-type and LBD mutant ARs comparably and inhibits the in vitro proliferation and in vivo growth of enzalutamide-sensitive and resistant prostate cancer xenografts. In preclinical models, UT-34 induced the regression of enzalutamide-resistant tumors at doses when the AR is degraded; but, at lower doses when the AR is just antagonized, it inhibits, without shrinking, the tumors. This indicates that degradation might be a prerequisite for tumor regression. Mechanistically, UT-34 promotes a conformation that is distinct from the LBD-binding competitive antagonist, enzalutamide, and degrades the AR through the ubiquitin proteasome mechanism. UT-34 has a broad safety margin and exhibits no cross-reactivity with G-Protein Coupled Receptor, kinase, and nuclear receptor family members. Collectively, UT-34 exhibits the properties necessary for a next-generation prostate cancer drug. MR49F cells (n=3-4/group) were maintained in charcoal-stripped serum containing medium for 48 hours and treated with vehicle, 0.1 nM R1881, or 10 uM of UT-34 in combination with 0.1 nM R1881. Twenty four hours after treatment, the cells were harvested, RNA was isolated and expression of genes was measured using microarray (Affymetrix Clarion S) UT-34 is a selective androgen receptor degrader that degrades and antagonizes the AR. UT-34 binds to the AF-1 domain of the AR and degrades the AR through ubiquitin proteasome pathways. The transcriptome study was performed to evaluate the ability of UT-34 to antagonize the enzalutamide-resistant AR function.

Dataset Information

Transcriptomic profiling of LNCaP cells treated with enzalutamide, olaparib, or combination across multiple time points

Dataset's files

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets